Clinical trials: Carcinomas
Non-Small Cell Lung Cancer
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC.
- Trial name
- NCT00633529
- Testing
- IMO-2055
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- EMD Serono
NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC
Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC
This is a randomized, open-label, phase 3 study evaluating nogapendekin alfa inbakicept (NAI) plus chemoimmunotherapy containing pembrolizumab and platinum-based chemotherapy versus chemoimmunotherapy alone as first-line…
- Trial name
- NCT07524257
- Testing
- Drug: Nogapendekin alfa inbakicept (NAI), Pembrolizumab, Cisplatin or Carboplatin
- Sponsor
- ImmunityBio, Inc.
Precancerous Conditions, Carcinoma
Identification of a Plasma Proteomic Signature for Lung Cancer
The primary objective is to identify a panel of plasma and/or serum proteins that differentiates the absence or presence of lung malignancy in samples obtained from subjects enrolled in this IRB/EC approved study with pulmonary…
- Trial name
- NCT01752101
- Where
- 12 sites in United States
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Integrated Diagnostics
Carcinoma, Non-Small Cell, Neoplasm Metastasis
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor.
- Trial name
- NCT00728390
- Testing
- PF-00299804
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Pfizer
Head and Neck Squamous Cell Carcinoma
A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis
To investigate what the body does to single doses of Sativex (i.e. the pharmacokinetics [PKs] of four sprays containing 10.8 mg Δ9 tetrahydrocannabinol [THC] and 10 mg cannabidiol [CBD]) when mild, moderate or severe oral…
- Trial name
- NCT01975688
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- GW Pharmaceuticals Ltd
Non Small Cell Lung Cancer, Small Cell Lung Cancer
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients…
- Trial name
- NCT07253142
- Testing
- HLX43 dose 1, HLX43 dose 2
- Where
- 10 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Henlius Biotech
Head and Neck Squamous Cell Cancer
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) versus standard treatment (methotrexate, docetaxel or cetuximab) for the treatment of recurrent or metastatic head and neck squamous cell cancer (HNSCC).
- Trial name
- NCT02252042
- Testing
- Pembrolizumab, Methotrexate, Docetaxel
- Volunteers
- 495 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC)
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig…
- Conditions
- Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
- Trial name
- NCT05652686
- Testing
- Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel.
- Where
- 15 sites in United States
- Volunteers
- 203 people
- Sponsor
- Phanes Therapeutics
Nasopharyngeal Carcinoma
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
This is an open label, phase Ib Study of SHR-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
- Trial name
- NCT04282070
- Testing
- SHR-1701, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma
MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.
Italian multicenter observational study to evaluate time to clinical hepatic decompensation, quality of life, effectiveness, and safety of tremelimumab plus durvalumab in patients with advanced or unresectable hepatocellular…
- Trial name
- MONTEROSA (NCT07607769)
- Testing
- STRIDE
- Where
- 24 sites in Italy
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Cervical Intraepithelial Neoplasia, Uterine Neoplasms
A Trial for Patients With Advanced/Recurrent Cervical Cancer
This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.
- Conditions
- Cervical Intraepithelial Neoplasia, Uterine Neoplasms, Genital Neoplasms, Female
- Trial name
- NCT00190983
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma, Non-small Cell Lung Cancer
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma, Triple-Negative Invasive Breast Carcinoma
- Trial name
- NCT02839954
- Testing
- anti-MUC1 CAR-pNK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Lung Cancer
Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061854
- Testing
- soblidotin
- Where
- 3 sites in United States
- Sponsor
- Daiichi Sankyo
Bladder Cancer, Urothelial Carcinoma
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
This is a clinical trial studying the administration of NanoDoce as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer
- Trial name
- NCT03636256
- Testing
- NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- NanOlogy, LLC
Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate
Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will receive oral doses of TRC253.
- Trial name
- NCT02987829
- Testing
- TRC253
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Hepatitis C Infection, Viruses
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant.
- Conditions
- Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human
- Trial name
- NCT01804829
- Testing
- Civacir® 10%
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Infigratinib is an oral drug which selectively binds to fibroblast growth factor receptor (FGFR) 2 and is being developed to treat participants with FGFR2 mutated cholangiocarcinoma.
- Trial name
- NCT03773302
- Testing
- BGJ398, Gemcitabine, Cisplatin
- Where
- 116 sites in United States, Australia and 13 more
- Volunteers
- 48 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Gastric Cancer, Gastroesophageal Junction Cancer
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
The primary objective is to evaluate the concordance between human epidermal growth factor receptor 2 (HER2) status determined by the participating laboratory and by the centralized laboratory.
- Trial name
- NCT02731313
- Testing
- Trastuzumab
- Where
- 19 sites in France
- Volunteers
- 420 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Renal Cell
Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have been administered with Nexavar for unresectable or advanced renal cell carcinoma (RCC).
- Trial name
- NCT01411423
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 3,305 people
- Sponsor
- Bayer
Colorectal Cancer, Non-Small Cell Lung Cancer
A Phase 1 Study of IM-1340 in Participants With Advanced Cancer
This study will test the safety and effectiveness of a drug called IM-1340 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with…
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm
- Trial name
- NCT07890246
- Testing
- IM-1340
- Volunteers
- 200 people
- Sponsor
- Immunome, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.